Synthetic studies on the indane SHIP1 agonist AQX-1125

Otto M. Dungan, Shawn Dormann, Sandra Fernandes, Brian C. Duffy, Daniel G. Effiong, William G. Kerr, John D. Chisholm

Research output: Contribution to journalArticlepeer-review

Abstract

AQX-1125 is an indane based SHIP1 agonist that has been evaluated in the clinic for the treatment of bladder pain syndrome/interstitial cystitis. To support our own studies on SHIP1 agonists as potential treatments for IBD and Crohn's disease, a new synthetic route to the SHIP1 agonist AQX-1125 has been developed. This sequence utilizes a hydroxy-acid intermediate which allows for ready differentiation of the C6 and C7 positions. The role of the C17 alkene in the biological activity of the system is also investigated, and this functional group is not required for SHIP1 agonist activity. While AQX-1125 shows SHIP1 agonist activity in enzyme assays, it does not show activity in cell based assays similar to other SHIP1 agonists, which limits the utility of this molecule.

Original languageEnglish (US)
Pages (from-to)4016-4020
Number of pages5
JournalOrganic and Biomolecular Chemistry
Volume20
Issue number19
DOIs
StatePublished - May 4 2022

ASJC Scopus subject areas

  • Biochemistry
  • Physical and Theoretical Chemistry
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'Synthetic studies on the indane SHIP1 agonist AQX-1125'. Together they form a unique fingerprint.

Cite this